Liquidia Corporation (LQDA)

Market Cap	6.33B +422.7%
Revenue (ttm)	288.07M +1,936.7%
Net Income	22.31M
EPS	0.24
Shares Out	88.93M
PE Ratio	291.78
Forward PE	17.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,693,893
Open	70.97
Previous Close	71.63
Day's Range	70.39 - 72.71
52-Week Range	11.85 - 72.71
Beta	0.59
Analysts	Strong Buy
Price Target	66.13 (-7.16%)
Earnings Date	May 11, 2026

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 216
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $66.13, which is a decrease of -7.16% from the latest price.

Price Target

$66.13

(-7.16% downside)

Analyst Consensus: Strong Buy